Health Canada Grants Approval for Ocaliva™ (obeticholic acid) for the Treatment of Patients with Primary Biliary Cholangitis (PBC)
NEW YORK, May 25, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that …